A good first step in encouraging oncology drug developers to embrace dose optimization would be to abandon the traditional term “Phase I” studies, National Cancer Institute Division of Cancer Treatment and Diagnosis Director James Doroshow suggested during a workshop co-hosted by the US Food & Drug Administration and the American Society of Clinical Oncology on 3 May and 5 May.
The workshop is part of FDA’s Oncology Center of Excellence’s efforts (“Project Optimus”) to urge drug developers to abandon the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?